摘要
目的观察托伐普坦对顽固性心力衰竭伴低钠血症患者临床症状及血浆BNP、CRP的影响。方法本院收治的112例顽固性心力衰竭伴低钠血症患者随机分为研究组和对照组,其中对照组56例给予常规基础治疗,观察组56例在对照组基础上加用托伐普坦治疗。治疗3 d后比较患者临床症状积分、24 h尿量、血钠、血钾等指标。结果研究组患者临床症状显著改善,24 h尿量、血钠较治疗前升高,CRP、BNP、LVP、IVS显著降低,且均显著优于对照组(均P<0.05)。结论对采用基础性治疗的顽固性心力衰竭伴低钠血症患者加用托伐普坦,可显著改善患者临床症状,降低心衰程度,维持钠、钾离子平衡,可临床推广。
Objective To observe the effect of tolvaptan on clinical symptoms and plasma levels of BNP and CRP in patients with refractory heart failure and hyponatremia.Methods 112 patients with refractory heart failure and hyponatremia in our hospital were randomly divided into study group and control group,in whom 56 patients in the control group were treated with routine basic treatment,and another 56 patients in the observation group were treated with tolvaptan on the basis of the control group.After 3 days of treatment,the scores of clinical symptoms,24 h urine volume,blood sodium,blood potassium,and other indicators were compared.Results The clinical symptoms of the patients in the study group were significantly improved,and the 24 h urine volume and blood sodium were increased,while the levels of CRP,BNP,LVP,and IVS were significantly decreased,which were significantly better than those in the control group(all P<0.05).Conclusion Tolvaptan can significantly improve the clinical symptoms of patients with refractory heart failure and hyponatremia on the basis of routine treatment,reduce the degree of heart failure,and maintain the balance of sodium and potassium ions,worthy of clinical promotion.
作者
邱乃艳
王珊珊
辛梅
Qiu Naiyan;Wang Shanshan;Xin Mei(Department of Cardiovascular Medicine,The Fifth People’s Hospital of Ji'nan,Ji’nan 250000,China)
出处
《国际医药卫生导报》
2020年第19期2869-2871,共3页
International Medicine and Health Guidance News
基金
济南市科技发展计划项目(2017-1-35)。
